877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC
Year: 2024
Type: article
Source: Annals of Oncology
Authors: N.F. Saba, K. Klinghammer, E. Castelluci, A.D. Colevas, T. Rutkowski, D. Thurner, U. Müller-Richter, M. Maio, J.S. Grewal, C.H.H. Ottensmeier, J. Dias, H. Yang, R. Das, J. Furlanetto, A-K. Herzfeldt, M-C. Kühnle, A. Ulges, J. Alles, Ö. Türeci, U. Sahin
Institutions: Emory University, Winship Cancer Institute, Stiftung Charité, Charité - Universitätsmedizin Berlin, Montefiore Medical Center, Stanford Medicine, Stanford University, The Maria Sklodowska-Curie National Research Institute of Oncology, Medical University of Graz, Universitätsklinikum Würzburg, University of Siena, Network Italiano Per la Bioterapia Dei Tumori, Norton Healthcare, University of Liverpool, BioNTech (Germany), BioNTech (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402561285